Conceptual foundations of the UCSD Statin Study: a randomized controlled trial assessing the impact of statins on cognition, behavior, and biochemistry.
暂无分享,去创建一个
Joel E Dimsdale | H. White | B. Golomb | M. Criqui | J. Dimsdale | Michael H Criqui | Halbert White | Beatrice Alexandra Golomb
[1] M. Hirt,et al. Variables Associated with Violence in a Forensic Population , 1988 .
[2] P. Morell,et al. Cholesterol for Synthesis of Myelin Is Made Locally, Not Imported into Brain , 1995, Journal of neurochemistry.
[3] Frederick K. Goodwin,et al. Aggression in humans correlates with cerebrospinal fluid amine metabolites , 1979, Psychiatry Research.
[4] S. Manuck,et al. The effects of fat and cholesterol on social behavior in monkeys. , 1991, Psychosomatic medicine.
[5] T. Pitts. Reduced Heart Rate Levels in Aggressive Children , 1997 .
[6] L. Råstam,et al. Low serum cholesterol concentration and short term mortality from injuries in men and women. , 1992, BMJ.
[7] B Barbiroli,et al. Coenzyme Q10 improves mitochondrial respiration in patients with mitochondrial cytopathies. An in vivo study on brain and skeletal muscle by phosphorous magnetic resonance spectroscopy. , 1997, Cellular and molecular biology.
[8] K. Kario,et al. Autonomic nervous system dysfunction in elderly hypertensive patients with abnormal diurnal blood pressure variation: relation to silent cerebrovascular disease. , 1997, Hypertension.
[9] A. Raine,et al. Psychophysiology of anger and violent behavior. , 1997, The Psychiatric clinics of North America.
[10] D. Lefer. Statins as potent antiinflammatory drugs. , 2002, Circulation.
[11] G. Davey Smith,et al. Should there be a moratorium on the use of cholesterol lowering drugs? , 1992, BMJ.
[12] I. McDowell,et al. Alzheimer’s disease: Insights from epidemiology , 2001, Aging.
[13] H. Lennernäs,et al. Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors , 1997, Clinical pharmacokinetics.
[14] E. Agner,et al. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. , 1997, Molecular aspects of medicine.
[15] J. Błasiak. Protective action of cholesterol against changes in membrane fluidity induced by methylparathion. , 1993, Acta biochimica Polonica.
[16] J. Lönnqvist,et al. Association of low serum total cholesterol with major depression and suicide , 1999, British Journal of Psychiatry.
[17] M. Nishikawa,et al. Effect of Treatment with 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitors on Serum Coenzyme Q10 in Diabetic Patients , 1999, Arzneimittelforschung.
[18] Tsuneyuki Yamamoto,et al. Characteristics in aggressive behavior induced by midbrain raphe lesions in rats , 1977, Physiology & Behavior.
[19] M. Åsberg,et al. 5-HYDROXYINDOLEACETIC ACID LEVELS IN ATTEMPTED SUICIDES WHO HAVE KILLED THEIR CHILDREN , 1984, The Lancet.
[20] T. Gross,et al. Deaths due to accidents and violence in two recent trials of cholesterol-lowering drugs. , 1990, Archives of internal medicine.
[21] V. Arango,et al. Evidence for the 5-HT Hypothesis of Suicide A Review of Post-mortem Studies , 1989, British Journal of Psychiatry.
[22] N. Hosomi,et al. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. , 1996, Atherosclerosis.
[23] G. Celesia,et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.
[24] G. Giustina,et al. Pravastatin-associated myopathy. Report of a case. , 1995, Recenti progressi in medicina.
[25] P. Durrington,et al. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon , 1997, British journal of pharmacology.
[26] P. McBride,et al. Benefits of Cholesterol Screening and Therapy for Primary Prevention of Cardiovascular Disease: A New Paradigm , 1998, The Journal of the American Board of Family Medicine.
[27] S. Manuck,et al. Effects of acute psychological stress on serum lipid levels, hemoconcentration, and blood viscosity. , 1995, Archives of internal medicine.
[28] R. Haley,et al. Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans. , 1999, Toxicology and applied pharmacology.
[29] M. Ansseau,et al. Harm avoidance and serotonin , 1999, Biological Psychology.
[30] A. Davison,et al. Cholesterol metabolism in myelin and other subcellular fractions of rat brain. , 1972, Journal of Lipid Research.
[31] P. Cowen,et al. Brain serotonin (5-HT) neuroendocrine function in patients taking cholesterol-lowering drugs , 1996, Biological Psychiatry.
[32] K. Miczek,et al. Neurobiological mechanisms controlling aggression: Preclinical developments for pharmacotherapeutic interventions , 1994, Neuroscience & Biobehavioral Reviews.
[33] P. Blain,et al. Interindividual Variations in Enzymes Controlling Organophosphate Toxicity in Man , 1992, Human & experimental toxicology.
[34] C. Furberg. Natural statins and stroke risk. , 1999, Circulation.
[35] V. Haroutunian,et al. Elevated Serum Total and LDL Cholesterol in Very Old Patients with Alzheimer’s Disease , 2001, Dementia and Geriatric Cognitive Disorders.
[36] Y. Watanabe,et al. Resolving a mystery: progress in understanding the function of adrenal steroid receptors in hippocampus. , 1994, Progress in brain research.
[37] Y. Sugiyama,et al. Uptake Is the Rate-limiting Step in the Overall Hepatic Elimination of Pravastatin at Steady-state in Rats , 1996, Pharmaceutical Research.
[38] W. Faustman,et al. Cholesterol and serotonin: Seeking a possible link between blood cholesterol and CSF 5-HIAA , 1994, Biological Psychiatry.
[39] John M. Gottman,et al. The relationship between heart rate reactivity, emotionally aggressive behavior, and general violence in batterers. , 1995 .
[40] J. Csernansky,et al. Platelet serotonergic markers and tridimensional personality questionnaire measures in a clinical sample , 1996, Biological Psychiatry.
[41] J. Hinton,et al. Catecholamine balance during stress anticipation: an abnormality in maximum security hospital patients. , 1978, Journal of psychosomatic research.
[42] B. Psaty,et al. The Association between Cholesterol and Death from Injury , 1994, Annals of Internal Medicine.
[43] E. Galas,et al. Interactions between ATP and cholesterol side-chain cleavage in mitochondria isolated from superovulated rat ovaries. , 1985, The International journal of biochemistry.
[44] U. Laufs,et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. , 1998, Circulation.
[45] E. Love,et al. Parkinson's disease and exposure to agricultural work and pesticide chemicals , 1992, Neurology.
[46] E. Coccaro. Central Serotonin and Impulsive Aggression , 1989, British Journal of Psychiatry.
[47] L. Costa,et al. Serum paraoxonase status: a major factor in determining resistance to organophosphates. , 1993, Journal of toxicology and environmental health.
[48] Hendriek C Boshuizen,et al. Blood pressure and mortality in elderly people aged 85 and older: community based study , 1998, BMJ.
[49] D. Jacobs,et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. , 1992, Archives of internal medicine.
[50] J. Reggers,et al. Harm avoidance dimension of the tridimensional personality questionnaire and serotonin-1A activity in depressed patients , 1997, Biological Psychiatry.
[51] Todd B. Sherer,et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.
[52] D. Filliol,et al. Cholesterol distribution in rat liver and brain mitochondria as determined by stopped-flow kinetics with filipin. , 1990, Archives of biochemistry and biophysics.
[53] G. Barr,et al. Effects of para-chlorophenylalanine and 5-hydroxytryptophan on mouse killing behavior in killer rats , 1978, Pharmacology Biochemistry and Behavior.
[54] K. Matthews,et al. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. , 1990, BMJ.
[55] J. Hubble,et al. Risk factors for Parkinson's disease , 1993, Neurology.
[56] J. Tuomilehto,et al. Cholesterol, depression and suicide , 2000, British Journal of Psychiatry.
[57] D. Jacobs,et al. Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial , 1992 .
[58] B. Bioulac,et al. Serotoninergic dysfunction in the 47, XYY syndrome. , 1980, Biological psychiatry.
[59] R. Collins,et al. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group. , 1997, European heart journal.
[60] E. Donetti,et al. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. , 1996, Cardiology.
[61] Statin-associated myopathy with normal creatine kinase levels. , 2003, Annals of internal medicine.
[62] M. Law,et al. Assessing possible hazards of reducing serum cholesterol , 1994, BMJ.
[63] E. Fosslien. Mitochondrial medicine--molecular pathology of defective oxidative phosphorylation. , 2001, Annals of clinical and laboratory science.
[64] C. Scapoli,et al. Serum cholesterol concentraions in parasuicide , 1995, BMJ.
[65] J. Hinton,et al. Relationship between Violence and Catecholamines , 1977, Perceptual and motor skills.
[66] B. Winblad,et al. Low blood pressure and dementia in elderly people: the Kungsholmen project , 1996, BMJ.
[67] K. Kantak,et al. Dietary tryptophan reversal of septal lesion and 5,7-DHT lesion elicited shock-induced fighting , 1981, Pharmacology Biochemistry and Behavior.
[68] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[69] M. Moskowitz,et al. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. , 2001, Stroke.
[70] M. Yamazaki,et al. Tissue-selective uptake of pravastatin in rats: contribution of a specific carrier-mediated uptake system. , 1996, Biopharmaceutics & drug disposition.
[71] K. Matthews,et al. Effects of lovastatin on cognitive function and psychological well-being. , 2000, The American journal of medicine.
[72] S. Manuck,et al. Demonstration of an association among dietary cholesterol, central serotonergic activity, and social behavior in monkeys. , 1994, Psychosomatic medicine.
[73] K. Laake,et al. Statins for the reduction of risk of Alzheimer's disease. , 2001, The Cochrane database of systematic reviews.
[74] G. M. Halmágyi,et al. Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors--simvastatin and pravastatin. , 1995, Australian and New Zealand journal of medicine.
[75] S. Nuttall,et al. The heart protection study: statins for all those at risk? , 2002, Journal of clinical pharmacy and therapeutics.
[76] J Beskow,et al. Depression and Suicide , 2006 .
[77] S. Nanko,et al. Low serum cholesterol and suicide attempts , 1994, British Journal of Psychiatry.
[78] A. Leon,et al. Low serum cholesterol level and attempted suicide. , 1995, The American journal of psychiatry.
[79] M. Davis,et al. p-Chloroamphetamine: short and long term effects upon shock-elicited aggression. , 1976, European journal of pharmacology.
[80] C. Vögele. Serum lipid concentrations, hostility and cardiovascular reactions to mental stress. , 1998, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.
[81] B. Golomb,et al. Statins and dementia. , 2001, Archives of neurology.
[82] W. Sessa. Can modulation of endothelial nitric oxide synthase explain the vasculoprotective actions of statins? , 2001, Trends in molecular medicine.
[83] K. Kantak,et al. Facilitation of shock-induced fighting following intraventricular 5,7-dihydroxytryptamine and 6-hydroxydopa , 2004, Psychopharmacology.
[84] M. Åsberg,et al. Neurotransmitters and Suicidal Behavior , 1997, Annals of the New York Academy of Sciences.
[85] L. Valzelli,et al. Fluoxetine activity on muricidal aggression induced in rats by p-chlorophenylalanine , 1983 .
[86] T G Ganiats,et al. Paradoxical survival of elderly men with high blood pressure. , 1989, BMJ.
[87] J. Dietschy,et al. Cholesterol metabolism in the brain , 2001, Current opinion in lipidology.
[88] A. Danysz,et al. Influence of coenzyme Q-10 on the hypotensive effects of enalapril and nitrendipine in spontaneously hypertensive rats. , 1994, Polish Journal of Pharmacology.
[89] R. Gregg,et al. HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture. , 1997, Toxicology and applied pharmacology.
[90] B. Golomb,et al. Insulin sensitivity markers: predictors of accidents and suicides in Helsinki Heart Study screenees. , 2002, Journal of clinical epidemiology.
[91] S. Lovestone,et al. The association between APOE and dementia does not seem to be mediated by vascular factors , 2000, Neurology.
[92] S. Luutonen,et al. High-density lipoprotein cholesterol levels of very old people in the diagnosis of dementia. , 1986, Age and ageing.
[93] S. Dimauro,et al. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency , 1997, Neurology.
[94] E. Ambrosioni,et al. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. , 2000, Journal of cardiovascular pharmacology.
[95] W. Agras,et al. Plasma lipid levels in patients with panic disorder or agoraphobia. , 1989, The American journal of psychiatry.
[96] M. Åsberg. Monoamine neurotransmitters in human aggressiveness and violence: a selective review , 1994 .
[97] Claude Lenfant,et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. , 2002, Journal of the American College of Cardiology.
[98] Factors associated with paradoxical survival at higher blood pressures in the very old. , 1991, American journal of epidemiology.
[99] C. Hennekens,et al. An overview of trials of cholesterol lowering and risk of stroke. , 1995, Archives of internal medicine.
[100] G. Omenn,et al. Species Differences in Serum Paraoxonase Correlate with Sensitivity to Paraoxon Toxicity , 1987 .
[101] M. Rodo,et al. Apolipoprotein E Genotype and Lipid and Lipoprotein Levels in Dementia , 2000, Dementia and Geriatric Cognitive Disorders.
[102] J. Nicolau,et al. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). , 1999, The American journal of cardiology.
[103] J. Gottdiener,et al. Effects of acute mental stress on serum lipids: mediating effects of plasma volume. , 1993, Psychosomatic medicine.
[104] Y. Shimada,et al. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. , 1996, Immunopharmacology.
[105] L. Grant,et al. Muricide after serotonin depleting lesions of midbrain raphé nuclei. , 1973, Pharmacology, biochemistry, and behavior.
[106] H. Mitani,et al. Inhibitory effects of fluvastatin, a new HMG‐CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol‐fed rabbits , 1996, British journal of pharmacology.
[107] J. Turgeon,et al. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. , 1998, Trends in pharmacological sciences.
[108] G. Kelly. Insulin resistance: lifestyle and nutritional interventions. , 2000, Alternative medicine review : a journal of clinical therapeutic.
[109] C. Furlong. PON1 status and neurologic symptom complexes in Gulf War veterans. , 2000, Genome research.
[110] M. Yamazaki,et al. Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinaemic rats. , 1996, Biopharmaceutics & drug disposition.
[111] G. Patten,et al. Dietary cholesterol influences cardiac beta-adrenergic receptor adenylate cyclase activity in the marmoset monkey by changes in membrane cholesterol status. , 1988, Biochimica et biophysica acta.
[112] S. Grundy,et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. , 2002, Stroke.
[113] K. Fuxe,et al. Basic fibroblast growth factor and steroid receptors in the aging hippocampus of the Brown Norway rat: Immunocytochemical analysis in combination with stereology , 1994, Neurochemistry International.
[114] G. Paxinos,et al. 5-Hydroxytryptamine depletion with para-chlorophenylalanine: Effects on eating, drinking, irritability, muricide, and copulation , 1977, Pharmacology Biochemistry and Behavior.
[115] Alan C. Wilson,et al. Central Nervous System Effects of HMG CoA Reductase Inhibitors: Lovastatin and Pravastatin on Sleep and Cognitive Performance in Patients with Hypercholesterolemia , 1994, Journal of clinical pharmacology.
[116] A. Alpérovitch,et al. Low blood pressure and risk of depression in the elderly , 2000, British Journal of Psychiatry.
[117] U. Ravnskov,et al. Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome. , 1992, BMJ.
[118] A. A. Khan. Cholesterol metabolism in the myelin of rat brain , 1968, Experientia.
[119] S. H. Koenig,et al. Cholesterol of myelin is the determinant of gray‐white contrast in MRI of brain , 1991, Magnetic resonance in medicine.
[120] G. Block,et al. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia. , 1993, British journal of clinical pharmacology.
[121] Abraham Weizman,et al. Serum cholesterol levels and suicidal tendencies in psychiatric inpatients. , 1994, The Journal of clinical psychiatry.
[122] R. Sorelle. Baycol withdrawn from market. , 2001, Circulation.
[123] S. Curry,et al. Lovastatin use and muscle damage in healthy volunteers undergoing eccentric muscle exercise. , 1991, The Western journal of medicine.
[124] J. M’buyamba-Kabangu,et al. J‐shaped relationship between mortality and admission blood pressure in black patients with acute stroke , 1995, Journal of hypertension.
[125] P. Cowen,et al. Dieting reduces plasma tryptophan and alters brain 5-HT function in women , 1990, Psychological Medicine.
[126] A. Catapano,et al. Pharmacology of competitive inhibitors of HMG-CoA reductase. , 1995, Pharmacological research.
[127] I. Buajordet,et al. [Statins--the pattern of adverse effects with empahsis on mental reactions. Data from a national and an international database]. , 1997, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.
[128] H. Pan. Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase , 2005, European Journal of Clinical Pharmacology.
[129] R. Langer,et al. Blood pressure change and survival after age 75. , 1993, Hypertension.
[130] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.
[131] S. Manuck,et al. Effects of a low-fat diet on brain serotonergic responsivity in cynomolgus monkeys , 1992, Biological Psychiatry.
[132] K. Kantak,et al. Dietary tryptophan modulation and aggressive behavior in mice , 1980, Pharmacology Biochemistry and Behavior.
[133] M. Pahor,et al. Hypertension and Primary Hypercholesterolemia Effect of the HMG-CoA Reductase Inhibitors on Blood Pressure in Patients With Essential , 1999 .
[134] Richard M. Lee,et al. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance , 1992, Clinical cardiology.
[135] R. D'Agostino,et al. Blood pressure and cardiovascular morbidity and mortality rates in the elderly. , 1997, American heart journal.
[136] S. Young,et al. Clinical response of aggressive schizophrenics to oral tryptophan. , 1983, Biological psychiatry.
[137] L. Vatten,et al. Low blood pressure and mortality in the elderly: a 6-year follow-up of 18,022 Norwegian men and women age 65 years and older. , 1995, Epidemiology.
[138] M. Åsberg,et al. Homicide, suicide and CSF 5‐HIAA , 1985, Acta psychiatrica Scandinavica.
[139] G. Patten,et al. The interaction of dietary fatty acid and cholesterol on catecholamine-stimulated adenylate cyclase activity in the rat heart. , 1987, Biochimica et biophysica acta.
[140] D R Wekstein,et al. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study. , 1996, JAMA.
[141] M. Mackness,et al. Low paraoxonase in Persian Gulf War Veterans self-reporting Gulf War Syndrome. , 2000, Biochemical and biophysical research communications.
[142] M. Hillbrand,et al. Serum cholesterol and aggression in hospitalized male forensic patients , 1995, Journal of Behavioral Medicine.
[143] D. Stoff,et al. Aggression and Violence: Genetic, Neurobiological, and Biosocial Perspectives , 1996 .
[144] J. England,et al. Muscle side effects associated with simvastatin therapy , 1990, The Medical journal of Australia.
[145] Nicola Cherry,et al. Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip , 2002, The Lancet.
[146] R. Balon,et al. Low cholesterol and violence. , 1998, Psychiatric services.
[147] B. Kasiske,et al. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? , 1996, The Lancet.
[148] M. Velussi,et al. Atorvastatin for the management of Type 2 diabetic patients with dyslipidaemia. A mid-term (9 months) treatment experience. , 1999, Diabetes, nutrition & metabolism.
[149] H. White,et al. Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndromes , 2002, Circulation.
[150] J. Ratey,et al. Buspirone treatment of aggression and anxiety in mentally retarded patients: a multiple-baseline, placebo lead-in study. , 1991, The Journal of clinical psychiatry.
[151] J. Simons. The $10 billion pill. , 2003, Fortune.
[152] Sarah K. Cotton,et al. Pesticide Use During the Gulf War: A Survey of Gulf War Veterans , 1999 .
[153] E. Vartiainen,et al. High serum cholesterol and risk of suicide. , 2000, The American journal of psychiatry.
[154] M. Virkkunen. Serum cholesterol levels in homicidal offenders. A low cholesterol level is connected with a habitually violent tendency under the influence of alcohol. , 1983, Neuropsychobiology.
[155] C. Shear,et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. , 1991, The American journal of medicine.
[156] S. Manuck,et al. Low or lowered cholesterol and risk of death from suicide and trauma. , 1993, Metabolism: clinical and experimental.
[157] H Jick,et al. Statins and the risk of dementia , 2000, The Lancet.
[158] Behavior and serum cholesterol in a social group ofCercopithecus aethiops , 2006, Primates.
[159] P W Macfarlane,et al. Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study , 2001, Circulation.
[160] M. Hillbrand,et al. Serum Cholesterol Levels and Severity of Aggression , 1993, Psychological reports.
[161] A. Engel,et al. Experimental Lovastatin Myopathy , 1993, Journal of neuropathology and experimental neurology.
[162] B. Ritz,et al. Parkinson's disease mortality and pesticide exposure in California 1984-1994. , 2000, International journal of epidemiology.
[163] I. Tsuji,et al. Nocturnal blood pressure and silent cerebrovascular lesions in elderly Japanese. , 1996, Stroke.
[164] G. Paxinos,et al. 5, 7‐dihydroxytryptamine lesions: Effects on body weight, irritability, and muricide , 1977 .
[165] R. Broderick,et al. Cholesterol-induced changes in rabbit arterial smooth muscle sensitivity to adrenergic stimulation. , 1989, The American journal of physiology.
[166] M. Hanefeld,et al. Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals , 1997, European Journal of Clinical Pharmacology.
[167] D. Blanchard,et al. ‘Taming’ of wild rats (Rattus rattus) by 5HT1A agonists buspirone and gepirone , 1988, Pharmacology Biochemistry and Behavior.
[168] M. Virkkunen,et al. Serum cholesterol in aggressive conduct disorder: a preliminary study. , 1984, Biological psychiatry.
[169] C. Hennekens,et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. , 1997, JAMA.
[170] B. Bioulac,et al. Biogenic amines in 47, XYY syndrome. , 1978, Neuropsychobiology.
[171] A. Gedye. Buspirone alone or with serotonergic diet reduced aggression in a developmentally disabled adult , 1991, Biological Psychiatry.
[172] G. de Pinieux,et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. , 2003, British journal of clinical pharmacology.
[173] S. Manuck,et al. Influence of dietary lipids on agonistic and affiliative behavior in Macaca fascicularis , 1996, American journal of primatology.
[174] A. Weverling-Rijnsburger,et al. Total cholesterol and risk of mortality in the oldest old , 1997, The Lancet.
[175] K. Ichihara,et al. Simvastatin and atorvastatin enhance hypotensive effect of diltiazem in rats. , 2001, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.
[176] N. Chu,et al. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. , 1997, European neurology.
[177] I. Hand,et al. Serum Cholesterol in Patients with Obsessive Compulsive Disorder during Treatment with Behavior Therapy and SSRI or Placebo , 2000, International journal of psychiatry in medicine.
[178] M. Stewart,et al. Serum Cholesterol in Antisocial Personality , 1981 .
[179] M. Hillbrand,et al. Serum Cholesterol Levels and Frequency of Aggression , 1994, Psychological reports.
[180] S. Yusuf,et al. Report of the Conference on Low Blood Cholesterol: Mortality Associations , 1992, Circulation.
[181] H. Hartung,et al. Pravastatin-associated inflammatory myopathy. , 1992, The New England journal of medicine.
[182] T. Abe,et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. , 2001, The Journal of pharmacology and experimental therapeutics.
[183] P. Rustin,et al. A case of mitochondrial encephalomyopathy associated with a muscle coenzyme Q10 deficiency , 1998, Journal of the Neurological Sciences.
[184] M. Speranza,et al. The inhibition of mitochondrial respiration by beta-benzal butyric acid and the possible relationship to cholesterol biosynthesis. , 1970, Biochemical pharmacology.
[185] A. Raine. Autonomic nervous system activity and violence. , 1996 .
[186] P. Elias,et al. Epidermal HMG CoA reductase activity in essential fatty acid deficiency: barrier requirements rather than eicosanoid generation regulate cholesterol synthesis. , 1992, The Journal of investigative dermatology.
[187] A. Mawson. On not taking the world as you find it-epidemiology in its place. , 2002, Journal of clinical epidemiology.
[188] K. Folkers,et al. Lovastatin decreases coenzyme Q levels in rats. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[189] G. Guyatt,et al. Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. , 1998, Annals of internal medicine.
[190] M. Pahor,et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. , 1999, Hypertension.
[191] J. Hallas,et al. Statins and risk of polyneuropathy: A case-control study , 2002, Neurology.
[192] R. Chilton. Lipid and Nonlipid Benefits of Statins , 2003, The Journal of the American Osteopathic Association.
[193] Y. Ichikawa,et al. Substrate-binding region of cytochrome P-450SCC (P-450 XIA1). Identification and primary structure of the cholesterol binding region in cytochrome P-450SCC. , 1993, Biochimica et biophysica acta.
[194] R Hen,et al. Enhanced aggressive behavior in mice lacking 5-HT1B receptor. , 1994, Science.
[195] G. Barr,et al. Manipulations of dietary tryptophan: Effects on mouse killing and brain serotonin in the rat , 1979, Brain Research.
[196] M. Marmot,et al. Lowering cholesterol concentrations and mortality. , 1990 .
[197] C. Sirtori,et al. Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors. , 1993, Pharmacology & therapeutics.
[198] Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin , 1996, The Lancet.
[199] G. Gabbiani,et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. , 1993, Atherosclerosis.
[200] A. Hoes,et al. Low serum cholesterol concentration and serotonin metabolism in men , 1996, BMJ.
[201] P. Bjerregaard,et al. High serum coenzyme Q10, positively correlated with age, selenium and cholesterol, in Inuit of Greenland. A pilot study , 1999, BioFactors.
[202] A. Raine,et al. Autonomic Nervous System Factors Underlying Disinhibited, Antisocial, and Violent Behavior Biosocial Perspectives and Treatment Implications a , 1996, Annals of the New York Academy of Sciences.
[203] A. R. Kuczmierczyk,et al. Serum Cholesterol Levels in Patients with Generalized Anxiety Disorder (GAD) and with GAD and Comorbid Major Depression , 1996, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[204] M. Uchiyama,et al. Effect of Pravastatin on Human Sleep , 1993, The Japanese journal of psychiatry and neurology.
[205] M. Sheard,et al. The effect of lithium on impulsive aggressive behavior in man. , 1976, The American journal of psychiatry.
[206] H. Sinzinger,et al. Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment. , 1999, Atherosclerosis.
[207] F. Song,et al. Cholesterol lowering and mortality: the importance of considering initial level of risk. , 1993, BMJ.
[208] B. Golomb. Cholesterol and Violence: Is There a Connection? , 1998, Annals of Internal Medicine.
[209] J. Salonen,et al. Determinants of plasma coenzyme Q10 in humans , 1999, FEBS letters.
[210] G. Leskin,et al. Elevated lipid levels in vietnam veterans with chronic posttraumatic stress disorder , 1999, Biological Psychiatry.
[211] Y. Yamori,et al. Pravastatin affects blood pressure and vascular reactivity , 2005, Heart and Vessels.
[212] G. Omenn,et al. Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. , 1990, Toxicology and applied pharmacology.
[213] L. Dobrucki,et al. Statin-stimulated nitric oxide release from endothelium. , 2001, Medical science monitor : international medical journal of experimental and clinical research.
[214] A. Faggiotto,et al. Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228)on migration, proliferation and cholesterol synthesis in arterial myocytes. , 1996, Pharmacological research.
[215] A. De Luca,et al. Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers. , 1995, The Journal of pharmacology and experimental therapeutics.
[216] P. Ducimetiere,et al. Serum cholesterol concentration and death from suicide in men: Paris prospective study I , 1996, BMJ.
[217] H. Sinzinger. Does vitamin E beneficially affect muscle pains during HMG-Co-enzyme-A-reductase inhibitors without CK-elevation? , 2000, Atherosclerosis.
[218] A. M. Lefer,et al. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. , 2001, Cardiovascular research.
[219] Y. Yamori,et al. HMG‐COA REDUCTASE INHIBITOR AFFECTS BLOOD PRESSURE AND VASCULAR REACTIVITY , 1995, Clinical and experimental pharmacology & physiology. Supplement.
[220] M. Linnoila,et al. CSF serotonin metabolite (5-HIAA) studies in depression, impulsivity, and violence. , 1990, The Journal of clinical psychiatry.
[221] M. Mccarty,et al. Toward a wholly nutritional therapy for type 2 diabetes. , 2000, Medical hypotheses.
[222] B. Golomb,et al. Low cholesterol and violent crime. , 2000, Journal of psychiatric research.
[223] M. Yamazaki,et al. Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinemic rats. , 1996, Biopharmaceutics & drug disposition.
[224] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[225] D. Brenneman,et al. Alteration of catecholamine uptake in cerebral cortex from rats fed a saturated fat diet , 1979, Brain Research.
[226] P. Sullivan,et al. Total cholesterol and suicidality in depression , 1994, Biological Psychiatry.
[227] J. Hinton,et al. Plasma catecholamines, stress and aggression in maximum security patients , 1978, Biological Psychology.
[228] B. Rosner,et al. Relationship of blood pressure to cardiovascular death: the effects of pulse pressure in the elderly. , 1999, Annals of epidemiology.